Start here if you're new
what it is
Intellia makes gene-editing medicine aimed at one-time treatments for hard diseases.
how it gets paid
Last year Intellia Therapeutic made $68M in revenue. collaboration revenue was the main engine at $26M, or 38% of sales.
why it's growing
Revenue grew 16.9% last year. Revenue rose 224% vs. prior year. The company still burned through cash on the way there.
what just happened
Intellia posted $45M in revenue, while EPS stayed at -$2.99.
At a glance
B balance sheet — gets the job done, barely
70/100 earnings predictability — reasonably predictable
-$3.81 fy2025 eps est
$2B fy2026 rev est
n/a operating margin
xvary composite: 42/100 — below average
What they do
Intellia makes gene-editing medicine aimed at one-time treatments for hard diseases.
You are buying a platform, not one pill. Intellia has 403 employees and a CRISPR/Cas9 engine, a gene editor, so one program can feed four in vivo targets. That gives you more shots than a single-drug shop, but the same setup also makes one bad readout hit the whole story.
How they make money
$68M
annual revenue · their business grew +16.9% last year
collaboration revenue
$26M
license and milestone revenue
$23M
grant revenue
$12M
other revenue
$7M
The products that matter
balance sheet reality
cash runway
$605M
This is the asset that buys time. Management said Q4 2025 cash should fund operations into 2027, which matters more than EPS for a company with no product revenue.
foundation
lead program
nex-z
1 of 2 priority assets
After the 2025 reorganization, this became one of the two programs carrying most of the thesis. If you own NTLA, this is one of the readouts you are really underwriting.
catalyst
second lead program
NTLA-2002
1 of 2 priority assets
This is the second serious card in the deck. Two credible programs are a pipeline. One credible program is a financing debate with better branding.
future
Key numbers
$2B
FY26 sales
That is 29x the $68M it booked over the last 12 months. The market is paying for a lab-to-commercial leap.
$68M
TTM revenue
This is the real revenue base today. Everything else depends on the pipeline hitting its marks.
$3.81
FY25 EPS
The company is still losing money per share. Growth is not paying the bills yet.
1.9
beta
The stock moves about twice as hard as the market. Your drawdowns will not be gentle.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $67M (4% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for NTLA right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Intellia posted $45M in revenue, while EPS stayed at -$2.99.
Revenue rose 224% vs. prior year. The company still burned through cash on the way there, so the growth came with a loss.
$45M
revenue
$2.99
eps
n/a
n/a
revenue
The $45M quarter matters because it showed 224% growth while the company still lost money.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is lead-program disappointment after the 2025 pipeline reset. With the story concentrated in two assets, weak data or a visible delay would hit both sentiment and financing leverage at the same time.
med
nex-z or NTLA-2002 loses credibility
The quiet part: this is a two-program stock now. If either lead asset slips on safety, durability, or timing, investors will not treat it like a small setback inside a broad pipeline.
Two lead programs carry most of the thesis. If one breaks, the market will start discounting the other harder too.
med
the runway shortens before a decisive readout lands
Management said $605M of cash funds operations into 2027. If trial timing stretches or spending rises, that window narrows and the financing question comes back fast.
With only $68M of annual revenue and a -416.15% pretax margin, the balance sheet carries the story until the clinic does.
med
good science still has to become a reimbursed drug
Gene editing does not just need to work. It needs to look safe, durable, and worth paying for in rare diseases where doctors and payers will compare it with existing options.
That means approval risk and commercial risk are stacked together, not separate chapters.
A forced rethink of either lead program would pressure a stock with a $2B market cap, $68M of collaboration revenue, and no approved product. That is a thin margin for narrative error.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next trial update window
You are waiting for the next meaningful data point from nex-z or NTLA-2002. In this stock, the calendar is part of the thesis.
trend
whether the two-program focus holds
Management simplified the story in 2025. Watch whether capital and commentary keep flowing to the same two assets or start drifting again.
risk
runway versus milestones
The key risk is not just cash burn. It is cash burn relative to progress. If time disappears faster than milestones arrive, your downside case gets louder.
metric
revenue quality
Track whether revenue stays stuck at collaboration income. $68M is useful funding. It is not proof that Intellia has crossed into a commercial phase.
Analyst rankings
short-term outlook
mixed
consensus target data is thin here. in human-speak: analysts do not have a clean shared view of what near-term success should look like.
risk profile
binary
A 1.9 beta and a 5 / 100 price stability score tell the story. This is a clinical readout stock first and a normal equity second.
chart momentum
event-driven
The chart will follow data timing, not tidy technical levels. A sentence from management can move the stock more than a quarter of revenue.
earnings predictability
70/100
That score looks decent, but the quarterly P&L matters less than whether the company can hold its runway into 2027 and keep the lead programs on track.
source: institutional data
Institutional activity
institutional ownership data for NTLA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$15
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive